Latest / Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
STEP HFpEF DM and Fair Allocation of Incretin-Based Therapies
In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, tackle a pair of related topics: what the STEP HFpEF DM trial from ACC.24 means for the diabetes community and the need for fair and equitable allocation of incretin-based therapies in the face of ongoing drug shortages and overwhelming demand.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.